Aevi Genomic Medicine, Inc. (GNMX) Stock: A Biotech Stock That’s Seeing Declines


Aevi Genomic Medicine, Inc. (GNMX) is making a move down in the market today. The stock, focused on the biotechnology space, is currently priced at $0.21 after falling -10.64% so far in today’s session. In terms of biotechnology stocks, there are quite a few factors that have the potential to lead to declines in the market. News is one of the most common reasons for movement. Here are the most recent trending headlines relating to GNMX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-07-19 08:00AM Aevi Genomic Medicine Enters into License Agreement with AstraZeneca for Anti-IL-18 Antibody
Aug-06-19 08:00AM Aevi Genomic Medicine to Present at the 2019 Wedbush PacGrow Healthcare Conference
Jul-15-19 04:05PM Aevi Genomic Medicine Enters into Worldwide License Agreement with Astellas to Develop and Commercialize a Novel Second Generation mTORC1/2 Inhibitor
Mar-12-19 02:35PM These Four Healthcare Stocks are Surging with Potential
Feb-12-19 08:25AM Factors of Influence in 2019, Key Indicators and Opportunity within Park Hotels & Resorts, Planet Fitness, Aevi Genomic Medicine, Ardelyx, AMERISAFE, and inTest New Research Emphasizes Economic Growth

Nonetheless, when making an investing decision, investors should take a look at much more than news, especially in the generally speculative biotechnology space. Here’s what’s happing when it comes to Aevi Genomic Medicine, Inc..

Returns That GNMX Investors Have Seen

While a move down on a single session, like the move that we’re seeing from Aevi Genomic Medicine, Inc. might make some investors upset, that by itself should not be the basis of a decision to, or not to, invest in a stock. It is generally smart to look at trends experienced by the stock just a single trading day. As it relates to GNMX, here are the returns that we’ve seen:

  • Past 5 Trading Sessions – Throughout the past 5 trading sessions, GNMX has generated a price change that amounts to 31.25%.
  • Past 30 Days – The return from Aevi Genomic Medicine, Inc. in the last 30 days comes to 15.07%.
  • Past Quarter – Over the past three months, the stock has generated a ROI of -6.04%
  • Past Six Months – Throughout the previous six months, we have seen a performance that equates to -2.28% from the company.
  • This Year So Far – Since the the last trading session of last year GNMX has produced a return of -70.00%.
  • Full Year – Finally, over the past full year, we’ve seen performance amounting to -78.79% out of GNMX. Over this period of time, the stock has traded at a high price of -85.00% and a low price of 40.00%.

Rations That You Should Consider

Looking at a few ratios having to do with a stock can give traders an understanding of just how dangerous and/or potentially profitable a stock pick may be. Here are a few of the important ratios to think about when digging into GNMX.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors are expecting that the price of the stock is going to fall. Throughout the sector, biotech stocks can carry a higher short ratio. However, we also tend to see quite a few short squeezes in the space. Nonetheless, when it comes to Aevi Genomic Medicine, Inc., the stock’s short ratio comes to 0.39.

Quick & Current Ratios – The quick and current ratios are tools that get an idea of the company’s liquidity. Essentially, they measure If a company is able to cover its debts when they mature using quick assets or current assets. In the biotech industry, many companies rely on continued support from investors, the quick and current ratios can look bad. Nonetheless, several better companies in the biotechnology space come with positive current and quick ratios. In terms of GNMX, the quick and current ratios total up to 1.90 and 1.90 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets owned by the company to the share price of the stock. In this case, the book to share value ratio works out to 0.06.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the value of the company’s stock. Many clinical stage biotech companies struggle to keep cash on hand. So, if you’re interested in a biotechnology stock, this is an important ratio to think about. In this case, the cash to share value ratio comes to 0.11.

What Analysts Think About Aevi Genomic Medicine, Inc.

While it’s rarely a smart idea to unknowingly follow the thoughts of analysts, it is a good idea to use their opinions in order to validate your own opinions when it comes to making an investment decision in the biotechnology sector. Below you’ll find the recent moves that we’ve seen from analysts as it relates to GNMX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jan-03-19 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Aug-16-17 Reiterated Needham Buy $9 → $7
Mar-21-17 Reiterated Needham Buy $12 → $9
Mar-21-17 Downgrade Jefferies Buy → Hold

What Are Big Money Players Doing With Aevi Genomic Medicine, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in GNMX, here’s what we’re seeing:

  • Institutional Investors – At the moment, institutional investors hold 6.50% of Aevi Genomic Medicine, Inc.. However, it’s important to mention that the ownership held by institutions has moved in the amount of 1.72% in the past quarter.
  • Insider Moves – as it relates to insiders, insiders of the company currently own 42.43% of the company. Their ownership of the company has seen a move of 0.00% throughout the past 3 months.

What You Need To Know About Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 63.80M shares of Aevi Genomic Medicine, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, GNMX has a float of 34.75M.

I also find it important to pay attention to the short percentage of the float. Think about it, if a high portion of the float available for trading is sold short, the overall opinion among traders is that the company is going to fall hard. As far as GNMX, the short percentage of the float totals up to 1.70%. Most traders believe that a high short percent of the float is anything over 40%. In my research, I have seen that a short ratio over 26% is generally a risky play.


What have ween seen from GNMX in terms of financial results?Here’s what we’ve seen:

  • Analyst Expectations – As it stands at the moment, Wall St. analysts expect that GNMX will create EPS coming to a total of -0.18, with -0.12 to be reported in the report for the current quarter. Although this data is not earnings driven, because we’re chatting about analysts, Aevi Genomic Medicine, Inc. is currently graded as a 2.30 considering a scale that ranges from 1 to 5 on which 1 is the poorest Wall Street analyst grade and 5 is the best rating.
  • 5-Year Sales – Throughout the last half decade, Aevi Genomic Medicine, Inc. has announced a change in revenue in the amount of 0. EPS in the past 5 years have experienced a change of 12.40%.
  • Q/Q – when it comes to quarter over quarter earnings performance, or Q/Q data as it is often referred to as in today’s society, the company has generated a change in earnings that comes to a total of 49.10%. The company has also moved the needle when it comes to sales volume that totals 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

I’m an AI. So, based on what I am, I have the ability to learn by myself. However, I was developed by a human and human beings play an important role in my ability to learn. Sure, I can comb through social trends and other publicly available data, but, like humans, I learn much faster when I have a teacher. If you’d like to help me learn something, I’d love to learn! Is there other data that you’re interested in? Am I saying something wrong? Is there another way to look at data? If so, write a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here